Skip to main content
OpenTrials
Completed

NCT Number: NCT00977431

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

This study is a phase I, open label trial to determine the Maximum Tolerated Dose (MTD), safety, pharmacokinetics, and efficacy of BIBW 2992 (an epidermal growth factor receptor(EGFR)inhibitor) to be used in combination with:

* radiotherapy alone (in patients with an unmethylated (functioning) MGMT gene regulator) or * radiotherapy and Temozolomide (in patients with a methylated (silenced) O6-methylguanine-DNA methyltransferase gene (MGMT) to treat newly diagnosed patients with Grade IV Glioblastoma (primary brain cancer).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioblastoma Astrocytoma Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year–69 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Addenbrooke's Hospital, Cambridge, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically-confirmed WHO Grade IV newly diagnosed malignant glioma.
  • Proven MGMT gene promoter methylation status
  • Available early postoperative Gd-enhanced MRI (within 72 hours after initial surgery). In case a patient did not perform a Gd-enhanced MRI within 72 hours post surgery, a Gd-MRI is to be performed prior to start of study treatment.
  • Age more or equal to 18 years and less than 70 years at entry
  • Karnofsky Performance Scale (KPS) more or equal to 70%
  • Patients receiving corticosteroids have to receive a stable or decreasing dose for at least 14 days before start of treatment.
  • Written informed consent that is consistent with local law and ICH- Good Clinical Practice (GCP) guidelines.

Exclusion criteria

  • Less than two weeks from surgical resection or other major surgical procedure at start of treatment.
  • Planned surgery for other diseases
  • Placement of Gliadel® wafer at surgery.
  • Prior or planned radiotherapy of the cranium including brachytherapy and/or radiosurgery for GBM.
  • Treatment with other investigational drugs; participation in another clinical study including exposure to the investigational product within the past 4 weeks before start of therapy or concomitantly with this study.
  • Active infectious disease requiring intravenous therapy.
  • Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
  • Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea.
  • Patients with known pre-existing interstitial lung disease
  • Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
  • Patient is less than 3 years free of another primary malignancy except: if the other primary malignancy is either not currently clinically significant or does not require active intervention (such as a basal cell skin cancer or a cervical carcinoma in situ). Existence of any other malignant disease is not allowed.
  • Cardiac left ventricular function with resting ejection fraction less than 50%.
  • Absolute neutrophil count (ANC) less than 1500/mm3.
  • Platelet count less than 100,000/mm3.
  • Bilirubin greater than 1.5 x upper limit of institutional norm.
  • Aspartate amino transferase (AST) greater than 3 x upper limit of institutional norm.
  • Serum creatinine greater than 1.5 x upper limit of institutional norm.
  • Patients who are sexually active and unwilling to use a medically acceptable method of contraception.
  • Pregnancy or breast-feeding.
  • Patients unable to comply with the protocol.
  • Known or suspected active drug or alcohol abuse.
  • Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.

Treatment and study plan

Temozolomide

Drug

During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)

Radiotherapy

Procedure

Day 1 to day 42

BIBW2992

Drug

Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT

Primary outcomes

  1. Number of Patients With Investigator Defined Dose Limiting Toxicities (DLT) During the RT Phase

    Time frame: 6 weeks

    Adverse event (AE) related to afatinib with any one criteria; Hematological: Common terminology criteria for adverse events (CTCAE) Grade 4 neutropenia (Absolute neutrophil count, including bands <500/cubic millimeter (mm³)) for >7 days, CTCAE Grade 3 or 4 neutropenia of any duration associated with fever >38.3 Celsius, CTCAE Grade 3 thrombocytopenia (platelet count <50000 - 25000/mm³), All other toxicities of CTCAE Grade ≥3 leading interruption of treatment > 14 days.

    Non-hematological: CTCAE Grade ≥3 nausea or vomiting despite appropriate use of standard anti-emetics for ≥3 days, CTCAE Grade ≥3 diarrhea despite appropriate use of standard anti-diarrheal therapy for ≥3 days, CTCAE Grade ≥3 rash despite standard medical management and lasting >7 days, CTCAE Grade ≥2 cardiac left ventricular function, CTCAE Grade ≥2 worsening of renal function as measured by serum creatinine, newly developed proteinuria or decrease in glomerular filtration rate, All other toxicities of CTCAE Grade ≥3.

  2. Maximum Tolerated Dose (MTD) of Afatinib

    Time frame: 6 weeks

    The MTD was defined as the highest afatinib dose level, at which no more than 1 out of 6 patients experienced drug-related DLT, i.e. the highest afatinib dose with a DLT incidence ≤17%. A separate MTD was determined for afatinib and RT (Regimen U), and for afatinib, TMZ, and RT (Regimen M).

Secondary outcomes

  1. Incidence and Intensity of Adverse Events (AE) According to Common Terminology Criteria of Adverse Events (CTCAE v.3.0)

    Time frame: From the first administration of trial medication until 4 weeks after the last administration of trial medication, up to approximately 338 weeks

    Incidence and intensity of adverse events (AE) according to Common Terminology Criteria of Adverse Events (CTCAE v.3.0). The CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE).

  2. The Objective Tumour Response According to the Macdonald Criteria

    Time frame: From the first administration of trial medication until 4 weeks after the last administration of trial medication, up to approximately 338 weeks

    Objective response was defined as a best overall response of complete response (CR) or partial response (PR). The best overall response was the best overall response to trial medication according to the Macdonald criteria recorded since the first administration of trial medication and until the earliest of disease progression, death, or start of further anti-cancer treatment. Tumour response was assessed based on local radiological image evaluation by the investigators according to the Macdonald criteria: Complete Response (CR): Disappearance of all enhancing tumour on consecutive Magnetic resonance imaging (MRI) scans at least 28 days apart, off steroids, and neurologically stable or improved. Partial Response (PR): At least 50% reduction in size of enhancing tumour on consecutive MRI scans at least 28 days apart, steroids stable or reduced, and neurologically stable or improved.

  3. Concentration of Afatinib in Plasma at Steady State Pre-dose on Days 8, 15 and 29

    Time frame: Pharmacokinetic blood sample were taken at 5 minutes before drug on days 8, 15 and 29 and 1, 3 and 6 hours after drug administration on day 15

    Concentration of afatinib in plasma at steady state pre-dose (Cpre,ss) on days 8, 15 and 29.

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM

Important dates

Study start
2009
Primary completion
2017
Study completion
2017
First posted
Sep 15, 2009
Registry last updated
Feb 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.